GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (FRA:CUS0) » Definitions » Cyclically Adjusted Revenue per Share

Curis (FRA:CUS0) Cyclically Adjusted Revenue per Share : €6.01 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Curis Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Curis's adjusted revenue per share for the three months ended in Mar. 2024 was €0.332. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €6.01 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Curis's average Cyclically Adjusted Revenue Growth Rate was -23.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -17.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -14.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -10.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Curis was -3.40% per year. The lowest was -17.30% per year. And the median was -8.50% per year.

As of today (2024-06-07), Curis's current stock price is €8.70. Curis's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €6.01. Curis's Cyclically Adjusted PS Ratio of today is 1.45.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Curis was 24.32. The lowest was 0.58. And the median was 6.24.


Curis Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Curis's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Cyclically Adjusted Revenue per Share Chart

Curis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.70 8.65 9.01 7.95 3.74

Curis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.13 7.05 7.47 3.74 6.01

Competitive Comparison of Curis's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Curis's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Curis's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curis's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Curis's Cyclically Adjusted PS Ratio falls into.



Curis Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Curis's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.332/131.7762*131.7762
=0.332

Current CPI (Mar. 2024) = 131.7762.

Curis Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 4.109 100.560 5.385
201409 1.593 100.428 2.090
201412 1.879 99.070 2.499
201503 1.420 99.621 1.878
201506 1.445 100.684 1.891
201509 1.419 100.392 1.863
201512 1.493 99.792 1.972
201603 1.202 100.470 1.577
201606 1.156 101.688 1.498
201609 1.186 101.861 1.534
201612 1.590 101.863 2.057
201703 1.403 102.862 1.797
201706 1.275 103.349 1.626
201709 1.400 104.136 1.772
201712 1.678 104.011 2.126
201803 1.211 105.290 1.516
201806 1.218 106.317 1.510
201809 1.472 106.507 1.821
201812 1.463 105.998 1.819
201903 0.943 107.251 1.159
201906 1.118 108.070 1.363
201909 1.562 108.329 1.900
201912 1.782 108.420 2.166
202003 1.423 108.902 1.722
202006 1.061 108.767 1.285
202009 0.853 109.815 1.024
202012 0.753 109.897 0.903
202103 0.402 111.754 0.474
202106 0.414 114.631 0.476
202109 0.564 115.734 0.642
202112 0.606 117.630 0.679
202203 0.408 121.301 0.443
202206 0.494 125.017 0.521
202209 0.608 125.227 0.640
202212 0.565 125.222 0.595
202303 0.444 127.348 0.459
202306 0.420 128.729 0.430
202309 0.464 129.860 0.471
202312 0.428 129.419 0.436
202403 0.332 131.776 0.332

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Curis  (FRA:CUS0) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Curis's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8.70/6.01
=1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Curis was 24.32. The lowest was 0.58. And the median was 6.24.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Curis Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Curis's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Curis (FRA:CUS0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (FRA:CUS0) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis (FRA:CUS0) Headlines

No Headlines